Antibe Therapeutics Inc.
ATE
Rank in Stocks
#31838
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Share Price
$0.21483059
Last synced: 2024-05-07
Market Cap
$11.13M
Change (1 day)
0.34%
Change (1 year)
-0.36%
Country
CA
Trade Antibe Therapeutics Inc. (ATE)
Category
Healthcare
Stock price history for Antibe Therapeutics Inc. (ATE)
Highest end of day price: $0.22 on 2025-04-01
Lowest end of day price: $4.78 on 2014-10-01
Lowest end of day price: $4.78 on 2014-10-01
Stock price history of Antibe Therapeutics Inc. from 2014 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2025 | -0.02% |
| 2024 | -64.79% |
| 2023 | 73.56% |
| 2022 | -33.35% |
| 2021 | -82.11% |
| 2020 | -6.13% |
| 2019 | 60.42% |
| 2018 | 70.25% |
| 2017 | -45.71% |
| 2016 | 86.85% |
| 2015 | -71.73% |
| 2014 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $100.56 | -21.15% |
US
|
|
| $93.07 | -2.88% |
IE
|
|
| $297.13 | -21.76% |
US
|
|
| $44.47 | -55.49% |
US
|
|
| $46.69 | -17.17% |
DE
|
